►
From YouTube: Open Source Antibiotics Science Update Oct 16 2020
Description
Weekly open project meeting for Open Source Antibiotics Series 2.
Full Project: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles
Relevant GitHub Issue: https://github.com/opensourceantibiotics/Series-2-Diarylimidazoles/issues/33
On the call: Professor Matthew Todd, Dr Dana Klug, Dr Edwin Tse, Giada Sabatino (all University College London), Dr Chris Swain (Cambridge MedChem Consulting), Anthony Sama, Ben Perry (DNDi),
A
Okay,
hello,
everybody
welcome
to
the
meeting
for
open
source
antibiotics
series
2
on
friday
october
16th.
I
will
just
share
my
screen,
which
should
hopefully
have
the
relevant
thing
on
it.
A
So
this
is
the
the
github
issue
that
dana
started
just
today
and
has
everything
I
think
that
we're
going
to
talk
about,
hopefully,
okay,
so
we
can
run
through
a
few
things
which
have
been
going
on
so,
firstly,
we
we
have
a
bunch
of
compounds
ready
for
for
evaluation
against
mercer,
which
is
great,
and
we
heard
back
from
paul
stapleton
who
is
happy
to
screen
those
compounds
next
week,
tuesday
right
there
that's
right,
yeah
and
which
is
great
because
there's
a
bunch
of
compounds
which
have
been
synthesized
and
donated.
A
So
it's
a
big
screen
this
one
we
so
you
know
we
haven't.
We
haven't
got
much
to
say
about
potency
until
we
get
those
data,
but
he
is
happy
to,
I
think
at
least
think
about
doing
an
evaluation
against
another
gram
positive.
So
we
were
talking
with
him
about
that.
He
is
able
to
do.
I
forget
the
vre
vancomycin-resistant
enterococci,
which
would
be
great,
so
he
can
do
that
and
I
think
he's
willing
to
do
that
with
a
few
compounds.
A
It's
obviously
you
know
it
takes
a
lot
of
effort
to
start
up
a
new
screen
and
the
building
has
been
in
lockdown
for
a
while.
So
it's
great
that
he's
able
to
to
do
this,
and
I
think
that
that
would
be
a
nice
one
to
go
for
as
a
second
grand
positive
just
to
remind
everybody,
we
have
a
bunch
of
data
from
co-out
of
the
at
the
beginning
of
this
project,
where
mrsa
was
the
only
gram
positive
that
was
tested,
all
the
gram
negatives
that
were
tested
by
coed.
A
Our
compounds
had
zero
activity
again.
So
so
you
know,
we
need
to
know
whether
something
specific
about
mercer
or
whether
it's
it's
just
that
these
compounds
are
currently
active
against
grain
positives.
So
this
would
give
us
a
second
screen
for
for
activity
against
the
grand
positive,
so
that'd
be
great.
It's.
B
A
The
you
know
who
high
priority
pathogen,
which
is
fantastic,
so
I
I
was
gonna.
I
was
in
a
conversation
with
paul
about
what
he
could
do
here
and
I
think
that
he's
willing
to
to
screen
a
few
compounds
and,
to
my
mind
what
that
should
be,
is
basically
you
know
two
or
three
actors,
a
couple
of
inactives
just
to
get
a
sense
of
whether
the
activity
tracks.
A
For
so
against
that
pathogen-
oh,
I
I
don't
know
yeah,
I
don't
know
what
that
is.
We
haven't
got
that
far
yet,
but
I
imagine
he
uses
something.
Did
you
have
something
in
mind.
C
A
C
A
So
that's
good
and
and
we'll
follow
up
on
that
with
with
a
plan.
I
don't
know
whether
that's
you
know
proposed
for
next
week,
but
but
it's
it's
a
good
one
to
start
with,
and
you
know
essentially,
if
there
is
activity
there
which
which
roughly
correlates
with
what
we've
seen
for
mercer,
then
we've
kind
of
answered
our
question
that
these
are
ground
positive
active
compounds.
A
I
think
in
as
much
as
we
need
to
yeah
all
right.
The
I
mean
the
rest
of
these
things
are
quite
brief,
so
I
I
was
gonna
well.
Let
me
just
run
through
a
couple
of
things
here.
So
the
we've
I
mean
essentially
a
lot
of
these
things
have
been
dealt
with
mechanism.
Action
stuff
is
ongoing,
we're
going
to
check
with
them
at
the
end
of
the
month.
A
Discussions
are
very
positive
with
high,
for
indeed
I
just
can't
talk
about
it
until
this
mou
is
signed,
which
is
tweaking
its
way
through
the
system,
and
then
we
can
reveal
everything
about
that.
But
the
positive
discussions
going
on
and
and
they're
interested
in
the
science
review,
which
is
also
great
and
I'm
still
waiting
for
something
from
gsk.
So
nothing
to
report
back
from
here,
and
I
don't
think
there
was
anything
else
that
was
majorly
important
for
for
this.
C
E
A
E
I
haven't
said
the
day
with
them,
so
paul
for
the
mrsa
essay
is
definitely
tuesday
and
then
I
just
told
andrea's
postdoc
and
his
grad
students.
I
checked
back
in
with
them
once
we
had
an
idea
of
which
compound
specifically.
A
D
It
would
be
interesting
to
see
what
the
one
with
the
fennel
on
the
bottom
egg.
Four
eight
four
eight
two
we'll
do:
human
cytotox,
because
yeah.
A
Thanks
for
reminding
me-
and
I
just
talked
about
that
the
other
day-
yes,
that's
a
key
experiment-
isn't
it
that
we
want
to
get
rid
of
the
the
two
pyradil
in
that
essay?
So,
yes,
we'll!
We
will
definitely
try
either
one
of
the
isomers
or
the
phenyl
compound,
or
both
to
test
that
theory.
Yeah,
fantastic
cool.
E
And
then
just
quickly
on
paul's
assay,
so
the
couple
of
questions
that
we
had
regarding
the
details
of
his
essay
just
put
that
in
the
comments
of
the
last
meeting.
I
don't
if
anybody
thinks
that
there's
a
better
place
to
put
it,
I'm
happy
to
put
it
there,
but
or
just
keep
it
there.
E
Yeah
yeah,
so
essentially
he
said
it's.
It
is
possible
that
there
could
be
metabolite
formation
under
that
assay
condition.
So
that
may
be
something
to
think
about
a
little
further,
but
he
said
he
couldn't
say
for
sure,
and
then
he
said
if
you're
comparing
the
ucl
versus
the
co-ed
results,
the
those
differences
are
in
line
with
what
you'd
expect
looking
at
the
two
protocols.
So
that's
fine.
E
A
Okay,
there
was,
I
have
I
hate,
having
actually
which
I
haven't
done.
Anything
about
the
this
comparison
between
the
the
data
ben
perry
forwarded
me
a
apparently
very
useful
thing
from
from
cyprotex
right,
a
manual
from
cyprotex,
and
I
was,
I
failed
in
a
very
clunky
way
to
download
that.
A
So
I
don't
know
if
anyone
has
done
that
work
already
and
knows
the
answer
about
the
fact
that
we
have
different
units
here
so
chris
last
time
you
were
talking
about
the
fact
that,
yes,
there
are
different
data
for
individual
and
in
vivo.
That
didn't
seem
to
be
our
issue
here.
B
A
A
That's
fine,
you
know
I.
I
should
take
take
more
responsibility
with
my
with
my
action
items
so
I'll
do
that
and
fix
it,
but
ben
seemed
to
think
it
wasn't
just
a
simple
error.
These
are
actual
things
and
we
have
to
be
careful
if
there's
some
sort
of
bizarre
order
of
magnitude
difference
between
the
data,
so
just
leave
it
with
me.
A
Okay,
I
think
that
was
everything
obvious
from
here.
So
can
we
should
we
talk
about
chemistry
while
we're
all
here.
F
Yeah-
it's
probably
not
too
much
this
week-
that's
all
right,
yeah!
So
just
my
stuff,
so
this
trifler
methoxy
compound
that
anthony
suggested.
So
I've
made
that
I
think
I
might
need
to
just
do
a
second
clean
of
it
because
there's
a
little
bit
of
baseline
stuff
and
then
these
so
the
pyrazine
and
pyrimidine
cores.
So
initially
this
bromination
with
bromine
was
pretty
messy.
F
So
I
kind
of
forgot
about
that
and
then
tried
this
method,
which
worked
there's
a
little
bit
of
pyridine
hydrobromide
left
over
from
that.
But
I
don't
think
it
matters
too
much
for
the
next
bits.
So.
F
Yeah,
well
I
mean
this
is
also
assault,
so
yeah,
but
yeah
I've
made
this
core
not
a
lot
of
it,
but
should
be
enough
to
do
the
brumination
and
then
the
suzuki.
Likewise
for
the
pyrimidines,
I've
made
this
bremer
ketone.
So
I
just
need
to
do
those
next
steps
and
then
I
should
have
those.
A
B
Yeah
then
I
have
a
question:
why?
Maybe
it's
stupid,
I
don't
know,
can
be
useful.
Maybe
try
with
an
hydrazine
like
instead
of
the
bromide
like
the
instead
of.
B
Instead
of
using
this
bromide
and
hebrew,
what
did
you
say.
E
G
A
A
I'm
guessing
you
know
in
some
cases
there
there's
always
alternatives.
You
can
suggest
for
doing
chemistry
and
in
some
cases
we
you
know
they've
been
tried
and
they
didn't
work
or
you
stick
with
what
works
you
know.
E
Yeah
yeah,
I
don't
have
much
too
much
new
this
week,
so
I've
been
wrestling
with
purifications,
so
these
are
just
the
structures.
I've
done.
The
box
keeper
take
protection
of
the
indole.
E
That's
messy
this
three
floral
compound
I
had
to
remake
and
on
then
also
I
need
to
re-purify
it.
So
hopefully
these
will
all
be
clean
by
tuesday,
but
it's
just
been
a
bit
of
a
pain
to
try
and
get
them
pure
enough.
E
I
used
hcl.
A
E
E
D
Almost
wonder
if
it
formed
a
hydrochloride
salt
with
the
with
the
naked
nitrogen
on
the
indole,
and
that
could
be
part
of
why
it's
messy.
A
A
E
So
I've
done
a
normal
phase,
column
on
that
and
I
had
to
use
ammonium
hydroxide
methanol
to
pull
it
down
and
then
so
after
that,
there's
still
some
impurities,
I
was
going
to
put
it
on
a
reverse
phase.
Actually
I
have
already
done
that
so
then
it's
just
need
to
concentrate
that
and
check
whether
that's
worked
or
not.
It
looks
like.
Maybe
it
has
okay,
so
I'm
cautiously
optimistic.
A
We
we
used
to
do
a
lot
of
debulking
on
cyclam
type
rings,
so
to
make
a
cyclone
which
is
a
ring
with
four
nitrogens
in
it
we
used
to
make
single,
armed,
cyclones,
and
so
the
way
to
do
that
was
have
three
of
the
nitrogen's
bot
protected,
and
then
you
do
your
chemistry
and
then,
at
the
last
minute
you
take
the
box
off
so
sort
of
glo,
nearly
globally
protection,
which
was
depressing
because
the
molecule
lost
so
much
mass.
A
You
know
you
ended
up
with
not
much,
but
it
was
very
common
there
that
if
we
didn't
have
a
little
bit
of
additives
in
our
debugging
mixture
of
water
and
what's
the
reagent,
it's
a
silent
reagent
that
we
would
see
reattachment
of
the
two
beta
group
onto
something
that
was
nucleophilic.
In
our
case,
it
was
true.
D
A
I
forget,
I
forgot
what
it
is.
Sorry,
it's
a
cocktail,
it
was
nice,
but
it
means.
A
H
A
Okay,
great,
thank
you
so
that
so,
what's
the
rough
tally
of
of
things
we're
sending
to
poor
for
the
evaluation.
E
I
think
it's
35
ish
there
are
16
dndi
compounds
from
tgc,
I
think
six
or
seven
from
northeastern
two
from
imperial
and
plus
the
ones
that
ed
and
I
have
made,
which
I
think
is
ten-ish.
Okay,.
A
F
D
F
A
Okay,
great,
it's
also
it's
nice
that
you've
got
the
the
powerpoint
here.
Building
yeah,
it's
like
it's
like
a
flick
book
of
chemistry
right
here,
you're
gonna,
you
know,
it'll
tell
you
the
whole
story
all
right.
I
think
that's
pretty
much
the
law
do.
I
do
I
mention
this
little
video
that
you're
gonna
make
again.
A
And
I
was
yeah,
so
the
only
thing
I
think
I
was
going
to
mention
is
that
which
is
very
small.
It's
not
a
science
thing.
Is
it's
just
a
way
of
of
keeping
people
in
touch
with?
What's
going
on
so
ever
since
we've
done
open
source
things,
I've
tried
to
think
about
what
is
the
best
way
of
keeping
people
in
touch
with
development,
and
we
use
this
obviously,
in
these
meetings
and
twitter
and
things
to
send
out
information
about
what's
happening
and
that's
fine.
A
A
lot
of
people
aren't
on
twitter
and
particularly
a
lot
of
more
senior
professors
are
not
on
twitter
and
it
would
be
nice
to
try
and
keep
people
in
touch,
and
we
often
thought
in
open
source
malaria
that
it
would
be
a
good
idea
to
have
newsletters
and
we
sent
out
one
with
mailchimp
that
took
us.
A
You
know
several
days
to
make
to
get
it
right
and
the
idea
was
to
send
you
know,
lots
and
stuff,
and
I
thought
that
would
be
quite
interesting,
but
it
is,
it
is
quite
demanding
to
do
one
that
looks
good,
even
though
it
does
reach
a
lot
of
people
and
people
tend
to
respond
to
simple
emails,
so
one
possibility
instead,
is
that
we
just
every
now,
because
there
aren't
that
many
people
who
who
you
know
are
interested
in
what
we're
doing
here
because
we're
early
stage,
but
it
could
just
be
that
we
every
now
and
again
we
send
an
email
out,
which
is
a
bit
like
this,
a
sort
of
distillation
of
the
most
important
things
that
happen
and
every
now
and
again
we
send
out
an
email
to
to
people.
A
A
I
just
wondered
if
anybody
had
any
thoughts
about
that
about
about
a
simple
low-time
investment
thing
that
would
allow
interested
people
to
see
recent
developments
in
a
in
a
much
shorter
form
than
what's
on
the
screen
and
and
in
a
way
that
perhaps
they
could
forward
to
people
who
might
be
interested
in
in
the
project.
Any
thoughts.
I
That's
strange
you
can
hear
me:
can
you
hear
me
now
yeah,
all
right,
cool,
so
yeah?
If
you're
gonna
do
that,
if
you're
gonna
do
the
mail
outs,
I'm
just
thinking,
don't
make
them
complicated,
don't
if
you,
if
you
may,
if
you
mailed
out
something
that
looks
like
these
minutes,
I'm
not.
A
I
That
is
incredibly
light,
incredibly
high
level
and
brief,
and
then
you
put
everything
else
in
back
up
somewhere
where
it's
like
you
know,
and
more
from
if
you're,
if
you're
interested
go
here,
you're
thinking
about
doing
video
updates
and
you
put
those
somewhere,
maybe
what
you
did
you
send
out
an
email
to
the
video
updates?
I
Yes,
in
the
video
update
as
long
as
you
you've
got
to
get
the
energy
level
right
in
the
video,
and
you
can
do
if
you
can
do
a
30-second
tick-tock
type
thing
of
like
here.
Is
you
know
you
can
use
the
latest
stuff,
but
you
get
it.
If
you
get
the
presentation
that
will
write,
that
would
be
really
cool
that
sounds
familiar
are.
I
I
But
anyway,
that's
that
I
mean
I
think
it's
an
interesting
idea:
you're
right,
that
twitter,
twitter,
twitter
is
brilliant
for
the
people
who
are
engaged
with
it.
It's
like
the
best
players
keeping
in
touch
with
people
engaged
with
it,
but
you
are
missing
a
subset
of.
G
I
Population-
I
guess
the
only
thing
I
would
ask
is
you
know
I
would.
I
think
the
venn
diagram
of
people
interested
in
contributing
to
open
source
farmer
and
twitter
users
is
pretty
close.
You
know
it's
pretty
overlapping.
A
Sure,
but
I
think
there
is
still
value
in
targeting
an
email
to
people
who
may
not
be
there.
I
mean
I'm
thinking
specifically
of
making
sure
that
an
email
has
a
chemical
structure
in
it,
because
a
lot
of
people
who
may
see
a
structure
and
then
think,
oh,
hang,
on
a
minute.
I
know
something
about
that,
may
not
be
on
twitter.
C
A
I
This
isn't
I'm
just
thinking
about
this
mac.
This
is
another
one
to
maybe
discuss
with
matt
robinson
at
code
with
moonshot,
because
they
have
a
daily
update,
email
that
comes
out,
and
it's
clearly
automated.
I
mean
there's
a
big
there's,
a
big
difference,
which
is
that
they
have
such
a.
They
have
such
a
critical
mass
so
that
they've
got
that
each
update.
It
does
bring
something
new
on
a
daily
basis.
I
The
question
would
be
you
know,
do
you
if
you
drop
that
down
to
once
a
week
or
you
drop
that
down
to
once
a
month?
Does
it
kind
of
get
lost
in
the
noise.
A
Yeah,
the
some
of
the
the
best
email
updates
I
get
are
from
essentially
from
carbex
john
rex's
antibiotics.
Emails
are
really
good,
but
that
they
are
they're
periodic
and
they
highlight
key
things
which
is
useful,
so
you're
reading
it
for
a
reason,
not
just
as
an
update.
You
know
some
new
development,
which
has
happened,
which
is
summarized
and
there's
there's
a
lot
there.
So
I
I
wouldn't.
C
Yeah
and-
and
I
I
quite
like
the
idea
of
it
being
if
you
like-
a
a
comment
to
these
minutes,
perhaps.
A
Yeah
yeah,
okay,
great
I
I
did
I
kind
of
wanted
to
avoid
going
through
a
client
like
mailchimp,
just
because
I
know,
there's
a
big
barrier
there
just
a
barrier
to
doing
it,
whereas
of
course
you
know
drafting
an
email
with
a
few
links,
maybe
a
picture
of
something
we
can
do
in
five
minutes.
Yeah.
A
I
I
I
You
know
generally
the
two
I
mean
when
we
get
when
we
get.
For
example,
if
you
get
data
reported
from
wushi
you're
from
basically
any
cro
they'll
for
each
experiment,
they'll
give
you
both
of
those
absolutely
some
people.
Some
people
will
in
fact
we
get
three.
We
get
four
readers,
you
also
get
half
life
and
you
get
extraction
ratio,
yeah
and
different
people
use
different
ones
as
their
kind
of
guiding
principle,
but
they
all
totally
agree
yeah.
This
is
what's
going
to
say.
Can
you
show
me
the
actual
image
where
the
problem
was.
A
Yeah,
so
the
problem
is,
we
said
we
have
in
vitro
data
from
two
places:
the
monash,
which
is,
of
course
very
familiar
to
us
and
original
unc
data
with
different
units,
and
you
know
we
initially
thought:
okay
they're
equivalent,
but
they're,
not
equivalent
they're,
an
order,
magnitude
out
michael
mill
and
so
they're
in
vitro
right.
So
they
shouldn't
be
different.
I
It's
made
no
because
the
the
monarch
status
that's
microliters,
per
milligram
of
protein
that
is
used
in
the
in
the
assay,
whereas
the
unc
data
that
is
the
exactly
they
would
you
they
could
express
that
as
a
microlibra
omega
protein.
But
it
would
be
a
different
value,
it
would
be
slightly
different
and
then
they
scale
that
using
a
bunch
of
different
I
mean
species
dependent
and
essay
dependence
vectors
to
give
you
a
pre
to
give
you
a
value.
That
is
what
it's
called
the
envy.
It's
called
the
in
vivo
intrinsic
clearance.
H
H
I
I
You
can
express
in
a
lot
of
different
ways
and
they
all
come
from
the
same
experiment.
They're
all
looking
at
the
same.
You
know
six
time
points
half-life,
usually
or
two
time
point
half-life.
If
you,
if
you're
only
doing
two
ten
points,
most
people
will
do
six
or
something
it's
very.
I
It's
lab
dependent
it's
dependent
on
how
long
they
incubate
for
it's
dependent
on
how
much
microbes,
how
much
how
much
microsoft
is
in
the
well
on
the
concentration
that
you
look
at,
and
so
that's
why,
with
as
long
as
the
essay
is
reported,
I
guess
in
theory
as
long
as
the
essay
is
as
long
as
you're
correlating
the
s.
The
same
essay
across
compounds,
then
the
actual
the
aurora
data,
the
microliter
pigment
mega
protein,
is
fine
to
compare.
I
If
you're
looking
at
different
assays
with
different
conditions,
then
you
would
be
better
off
comparing
the
currently
in
vivo
prediction,
so
the
one
in
melbourne
in
the
cake,
because
those
should
all
be
independent
of
assay
conditions
in
theory,
bear
in
mind
we're
talking
about
essays.
That
vary
massively
all
the
time.
I
Or
money
yeah
I
mean
it's
easy,
you
would
yes,
I
mean
you
could
take
either
or
you
ask
monash.
To
I
mean
the
monastery
is
coming
from
shaman,
I'm
guessing
right.
Yep
go
just
ask
sue
who
asks
karen?
Is
it
karen?
What
you
know
karen's
the
viva
person
ask
someone
at
cdc,
no
sure
either
go
straight
to
german
or
you
know
someone
you
work
with
and
just
say
look.
This
is
the
deal.
We've
got
this
unc
data
which
is
expressed
in
this
and
they'll.
A
I
It's
it's
not
a
dumb
question.
It's
a
really
complicated
question
that
everyone
struggles
with,
because
you
know
I
mean
particularly
you
know,
dmdi,
where
we
have.
Sometimes
we
have.
You
know
tri-party
meetings
with,
let's
say
gsk
and
dundee,
both
of
whom
are
real
experts
in
in
in
in
me,
and
then
us
and
our
data
comes
in
one
unit.
I
That's
the
other
one
yeah
yeah
exactly
in
in
in
exactly
but
it,
but
my
gut
feeling
is
that
your
va
is
that
generally
a
microliter
omega
protein
value
should
be
roughly
comparable.
Anyway,
you
know
if
you're
at
40
microliters
per
minute
make
a
protein
in
a
mouse.
Your
equivalent
in
melbourne
will
be
about.
I
can't
remember,
which
way
it
goes
you'll
either
be
in
the
30s
or
it'll,
be
in
the
50s.
A
I
A
I
Depending
on
the
assay
and
the
assay
conditions,
all
right,
it's
about
the
same
thing!
So
that's
why,
when
you
said
that
there
was
no
order
of
magnitude
checked,
I
was
worried
that
you
had,
for
example,
the
same
compound
measured
in
both
values
and
one
was
reading
at
50
and
one's
reading
at
500..
So.
A
The
only
comparable
data
we
have,
if
you
notice
the
unc,
has
the
asterisk.
Can
I
make
this
bigger?
I
can't
make
it
bigger.
Hang
on
a
second.
I
was
trying
to
make
it
slightly
larger,
okay,
so
the
the
only
comparable
data
these
asterisk
values-
17.7
142,
are
from
unc
and
the
data
beneath
it
are
from
monash
okay,
so
they
are,
they
are
broadly
equivalent.
A
They
are
yeah
pretty
much
and
and
if
you
look
at
the
data,
the
mouse
data
I
mean
you
know,
there's
differences,
but
there
are
again
broadly
equivalent
in
the
sense
that
the
smallest
value
in
the
mass
column
is
the
smallest
value
in
the
rat
and-
and
you
know
it
roughly
roughly
tracks
in
terms
of
order.
So
I
was
very
happy
with
the
idea
that
these
are
saying
that
roughly
the
same
thing.
I
Yeah,
okay
yeah
they
are,
I
mean,
bear
in
mind
that
it's
quite
common
to
see
discrepancies
across
species
yeah,
even
even
with
most
tourettes
and
human
as
well.
But
in
fact,
in
fact
you
would
say
that
it's
you,
you
give
it
as
a
as
a
plus
point
to
the
series,
if
they're,
if
the
series
tracked
like
that,
so
it's
like
if
the
microphone
is
in
it's
whether
same
rank
across
species,
that's
usually
a
good
thing.
A
Right
yeah,
I
mean
in
this
case
as
well
in
this
project
we're
due
to
get
another.
I
think
it
is
four
measurements
from
sue
and
so
we'll
end
up
with
a
bunch
of
data
from
sue
and
a
relatively
small
amount
of
data
from
unc.
So
in.
In
that
sense,
I
guess
what
I'm?
What
I'm
hoping
for
is
that
we
can
just
have
a
simple
clarification
of
the
unc
value
rather
than
the
monash
value.
Wait.
I
H
I
Did
then
I
did
now
if
I,
if
I
have
I'm
almost
certain
I'll,
send
that
to
you
and
michael
it's
been
make
a
protein,
but
I
have
that
data
also
in
melbourne.
So
what
I'll
do
is?
I
can
update
it
and
I'll
give
you
like
I'll,
give
you
the
half-life
I'll,
give
you
the
the
extraction
ratio
and
then
the
two
different
values
you
see
here.
Just
so,
you
can
kind
of
get
a
flavor
as
to
you
know
how
they
all
collect,
because
they
all
come
from
the
same
experiment.
I
I
They
use,
I
pretty
certain
that
he
said
he's
likely
to
make
yeah
reporting,
bearing
in
mind
you
can't
car,
you
can't
you
can't
you
can't
completely
correlate
that
or
assume
you
can't
assume
it's
the
same
essay
as
other
people
are
reporting
in
the
same
units
because
it
might
be
slightly
different
in
terms
of
incubation
time.
It
might
be
slightly
different
in
terms
of
concentration
of
compounds
and
stuff
like
that
right,
but
generally
generally,
they
all
are
kind
of
similar.
I
Well,
that's
a
good
question
I'll
check,
okay,
because
because
some
of
the
data
we
generated
on
those
compounds
has
been
done
at
his
head
and
some
of
them
done.
I
I
wish
he
okay,
yeah
yeah.
Probably
those
two.
I
don't
think
you
know
what
I
don't
think
we
would
have
done
anything
with
tcg
as
well,
but.
C
I
We
yeah
yeah
and
we
yes
true
and
it
might
be
different
positive
controls
in
different
lives.
Of
course
yeah.
I
think
what
we
used
to
testosterone,
maybe.
I
But
we
don't
report
the
data
unless
those
are
all
three
of
them.
They
are
in
the
control
value.
Okay,
so
it
only
ever
gets
validated
if
the
all
three
like
the
low,
medium
and
high
controls
are
within
the
room,
bearing
in
mind
that
you
know
azad
wushi,
these
guys
run
hundreds,
if
not
thousands
of
these
a
week.
F
A
A
Great
anything
else
anyone
wanted
to
raise.
If
not,
then
thanks
for
your
time,
that's
great,
we'll,
post
the
recording
and
some
action
items
and
we'll
me
next
week,
danny
you're,
not
here
right,
but
we
will.
We
will
probably
meet
anyway.
E
A
Yep
great
all
right:
well,
it's
going
to
be
pretty
interesting.
Let's
finish,.